Celgene licenses GlobeImmune cancer candidate

Celgene Corp. (NASDAQ:CELG) exercised its option to license exclusive, worldwide rights to oncology candidate GI-6207 from

Read the full 162 word article

How to gain access

Continue reading with a
two-week free trial.